Joanne Holland
Directeur Technique/Scientifique/R&D chez CONDUIT PHARMACEUTICALS INC.
Postes actifs de Joanne Holland
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Directeur Technique/Scientifique/R&D | 19/03/2024 | - |
Historique de carrière de Joanne Holland
Anciens postes connus de Joanne Holland
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - | 31/05/2021 |
| Directeur Technique/Scientifique/R&D | - | 31/05/2021 | |
| NUFORMIX PLC | Directeur/Membre du Conseil | 01/01/2008 | 31/05/2021 |
| Directeur Technique/Scientifique/R&D | 01/01/2008 | 24/05/2021 | |
| Fondateur | 01/01/2008 | 31/05/2021 |
Formation de Joanne Holland
| University of Leeds | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 4 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Joanne Holland
- Expérience
